Shop Talk : Oncology Times
An abstract is unavailable.
Related Articles
Factors Influencing Optimal Bracing Compliance in… : Spine
influencing optimal brace compliance to achieve brace treatment success remain unknown. Materials and Methods. This study included AIS patients aged 10 to 15, with a…
National Coordinator With International Consortium on Acute Leukemia Shares Progress, Challenges | ASH News Daily | American Society of Hematology
The International Consortium on Acute Leukemia (ICAL), a network strongly supported by ASH, brings together clinical investigators from Europe, North America, and South America to…
CME / CE – Physicians’ Education Resource
Physicians’ Education Resource – Newest Continuing Medical Education Live Events, Webcasts & Online Activities
IASLC Lectureships Honor the Work of Thoracic Oncology Trailblazers – ILCN.org (ILCN/WCLC)
Nine difference-makers in the field of lung cancer shared their groundbreaking work during the IASLC Lectureship Awards presentations at WCLC 2024.
The Use of HCT for Hematologic Cancers Across Patient Groups : Oncology Times
An abstract is unavailable.
GSDME-mediated pyroptosis contributes to chemotherapy-induced platelet hyperactivity and thrombotic potential
Key PointsCisplatin induces platelet pyroptosis via the activation of the caspase-3–GSDME axis.Loss of GSDME protects mice from cisplatin-induced platelet
Innovative mRNA CAR Therapy MT-303 Under Study for Liver Cancer
MT-303, a novel GPC3-targeting mRNA/lipid nanoparticle chimeric antigen receptor therapy, enhances cytokine-driven immune response and tumor cytotoxicity.
Fresh CAR T-Cell Therapy Zamto-Cel Elicits Responses in Rel/Ref DLBCL – Oncology Nurse Advisor
Zamto-cel is an autologous, CD20- and CD19-directed, non-cryopreserved CAR T-cell therapy.
Program: Monday, February 24
monday, february 24 continental breakfast 7-8 a.m. Major Symposium 1: Personalized Therapies Targeting Neoantigens 8-9:30 a.m. Session Chair: Alena Gros, VHIO Vall D’Hebron Institute of…
Daiichi Sankyo, AstraZeneca Withdraw EU MAA for Dato-DXd in Advanced Nonsquamous NSCLC
European approval is no longer being sought for Dato-DXd in advanced nonsquamous non–small cell lung cancer.
